Matrix Pro is one applicator on a three-applicator machine, and that is the difference that matters. It sits on Candela's Profound Matrix platform alongside Sublative RF, a non-needle pin array, and Sublime, a non-invasive heating handpiece. Morpheus8 is a family of needle tips - 12, 24 and 40 pins - used on InMode's radiofrequency consoles.
Matrix Pro's cleared wording names a cosmetic use. Morpheus8's does not. Matrix Pro is cleared for general dermatological procedures for electrocoagulation and hemostasis - surgical language for sealing tissue and stopping bleeding - and separately for the percutaneous treatment of facial wrinkles, meaning through the skin, in Fitzpatrick skin types I to IV (K240070, July 2024). Morpheus8's clearances read electrocoagulation and hemostasis (K192695, December 2019) and coagulation or contraction of soft tissue (K231790, July 2023). No cosmetic use appears in either.
If a clinic offers you "ablative plus radiofrequency in one visit", ask which applicator does which part. On the Profound Matrix, ablation and resurfacing belong to Sublative RF, not to the needle applicator. The same split exists on InMode's side: its Fractora applicator with the 60-pin tip is cleared for ablation and resurfacing, and Morpheus8 is not. Neither needle applicator is a resurfacing device.
The other two applicators on the platform are Sublative RF, a non-needle pin array, and Sublime, which heats without breaking the skin.
InMode's separate Fractora applicator covers resurfacing; Morpheus8 does not.
Its operating frequency is not stated in the FDA summary, and nor is whether the needles are insulated.
On the same platform, Sublative RF is cleared for ablation and resurfacing of the skin and for facial wrinkles, limited to Fitzpatrick I to IV above 62 millijoules per pin; Sublime is cleared for non-invasive wrinkle treatment. Acne scars appear in none of them, and cellulite belongs to a different Candela product entirely.
Above 62 millijoules per pin, Morpheus8 is limited on-label to Fitzpatrick skin types I to IV.
Published protocols in this field cluster at three sessions, three to eight weeks apart. Because three applicators share the platform, ask how many of your visits are for the needle one.
Candela sells two things with "Profound" in the name, and they are not interchangeable.
The original Profound System was cleared in September 2016, filed in a different FDA product category from the newer machine, and it carries a real cosmetic indication: percutaneous treatment of facial wrinkles on its 25-degree dermal handpiece, and improving the appearance of cellulite on its 75-degree handpiece in Fitzpatrick skin types I to III, backed by six-month clinical data submitted with the application. It uses temperature sensors that hold tissue between 65 and 75 degrees Celsius, and a multicentre trial of 50 people reported 93 per cent success at six months for cellulite by blinded physician grading.
None of that belongs to Matrix Pro. Matrix Pro is a different applicator, cleared later, filed under a different FDA product category, with impedance monitoring rather than temperature sensors, and no cellulite indication. If a clinic cites the Profound cellulite research while treating you with Matrix Pro, the research does not apply to the machine in the room.
No published trial names Matrix Pro or the Profound Matrix platform. No published trial of Morpheus8 is a randomised controlled trial either - a PubMed search returns 16 records in total, several of them in industry-sponsored journal supplements.
What does exist is class-level. Atrophic acne scars are the best-evidenced use: a systematic review of 16 studies and 481 patients, including 6 randomised trials, found the treatment "likely" effective on its own, and a 2026 split-face trial in which the assessors did not know which side had which treatment found no significant difference from fractional CO2 laser, with less downtime and fewer episodes of darkened skin afterwards. Six months is where the measured evidence stops. No controlled study has followed anyone longer.
The wrinkle indication is real and it is narrow: Fitzpatrick I to IV, that applicator only, and reviewed rather than proved. Ask which applicator is being used on which visit.
An analysis of the FDA's postmarket reporting database from 2013 to 2025 found 114 reports containing 224 events across radiofrequency microneedling devices: 56 textural changes, 41 pigment changes and 26 involving fat loss. That database is voluntary and has no denominator, so none of it can be read as your odds; set against it, a split-face study in 30 people measured the fat layer under the chin with ultrasound and found the dermis thickened while the fat layer did not change significantly.
If you get cold sores, say so when you book, not on the day. Antiviral medicine is started in advance, so it has to be prescribed beforehand. There is no published data on cold sore reactivation after radiofrequency microneedling specifically; the precaution comes from laser resurfacing, where reactivation is well documented.
Also disclose a pacemaker or implantable defibrillator, and any metal implant in or near the treatment area. These are labelled contraindications for radiofrequency devices generally, precautionary rather than tested, and your cardiology team is the right source of advice.